International Business Times·2025-11-01 14:22Core Points - Pfizer Inc. has initiated a lawsuit against Metsera Inc. and Novo Nordisk A/S to block Novo's acquisition bid for Metsera, which is developing treatments for obesity and diabetes [1][2] - Pfizer argues that Novo's offer does not qualify as a "Superior Company Proposal" due to significant regulatory challenges, and seeks a temporary court order to prevent Metsera from finalizing any deal with Novo [2][4] - Novo Nordisk's bid for Metsera is at least $6.5 billion, potentially increasing to $9 billion based on performance targets, which is approximately 11% higher than Pfizer's offer [4] Regulatory and Legal Context - The Federal Trade Commission has cleared Pfizer's acquisition of Metsera, removing a waiting period that would have ended on November 7, thus satisfying regulatory review requirements [3] - Pfizer's lawsuit claims that Novo's bid is "reckless" and may misuse a dominant market position to hinder competition, while Novo has stated it will vigorously defend against these claims [5][6] Market Reaction and Timeline - Following the announcements, Pfizer's shares increased by 0.2% in postmarket trading, while Metsera's shares fell by 1.8%, and Novo's shares remained unchanged [7] - Pfizer has until November 4 to respond with a counteroffer or withdraw from the deal, indicating a tight timeline for the company [6]